Axcan has entered into an agreement to acquire Mpex Pharmaceuticals, Inc. and its lead product candidate, Aeroquin, a new aerosol formulation of levofloxacin. Aeroquin is currently in Phase III development for the treatment of pulmonary infections in patients with cystic fibrosis (CF). Mpex will receive an upfront payment and a series of regulatory and success-based payments, but financial details were not disclosed. The acquisition, subject to customary closing conditions, is expected to close ...